Evoke Pharma Receives Notice of Allowance from United States Patent and Trademark Office for a Method of Use Patent with Claims Covering Gimoti®
“We are pleased with this additional USPTO determination that Gimoti is innovative and novel. We believe Gimoti provides an important option for treating diabetic gastroparesis patients with nasal delivery, especially as the disease can cause patients to experience delayed digestion of oral medications,” commented
Evoke is a specialty pharmaceutical company focused primarily on the commercialization and development of drugs to treat GI disorders and diseases. The company developed GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in
Safe Harbor Statement
Evoke cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negatives of these terms or other similar expressions. These statements are based on Evoke’s current beliefs and expectations. These forward-looking statements include statements regarding Evoke’s expectations on the scope of any patent protection. The inclusion of forward-looking statements should not be regarded as a representation by Evoke that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties associated Evoke’s ability to obtain and maintain intellectual property protection for GIMOTI and other risks and uncertainties inherent in Evoke’s business, including those described in Evoke’s periodic filings with the
Source: Evoke Pharma, Inc.